The Pharma Data

JUNE 6, 2025

Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3 In the U.S.,

Pharmaceutical Companies 40

Pharmaceutical Companies Compliance Pharmaceuticals International 40

Perficient: Drug Development

FEBRUARY 20, 2024

Prescription drugs reach patients through a complex web of entities. Among these, pharmacy benefit managers (PBMs) play a crucial role, handling reimbursements and negotiations with drug manufacturers and pharmacies. Unpacking Concerns in the PBM Landscape: The Catalysts The PBM landscape is rife with tension.

Pharmacy 52

Pharmacy Independent Pharmacies Doctors Pharmaceuticals 52

Alta Sciences

OCTOBER 30, 2023

Podcast : FDA Guidance for Industry Psychedelic Drugs Extensively studied for potential therapeutic efficacy, psychedelic drug development comes with its own set of clinical development requirements. Watch the video. TOP MANUFACTURING AND ANALYTICAL RESOURCES The Altascientist : Issue No. Listen here. Read or listen now.

Science 52

Science Clinical Trials Pharmacokinetics Pharmacy 52

Perficient: Drug Development

MARCH 14, 2024

In fact, the global healthcare eCommerce market is projected to reach $994.2 3 Ways Adobe Commerce Elevates Pharmacy Services The ability to offer healthcare products and services digitally is more important than ever. billion by 2030. But a complex regulatory landscape and data privacy and security concerns are formidable obstacles.

Science 52

Science Pharmacy Marketing Production 52

The Pharma Data

JANUARY 13, 2021

14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. We are excited to attract such top tier talent from the psychedelic drug development community.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

Perficient: Drug Development

FEBRUARY 13, 2024

3 Ways Adobe Commerce Elevates Pharmacy Services Billion by 20301 – but a complex regulatory landscape and concerns over data privacy and security are formidable obstacles. Check out our blog series that discusses different use cases for HIPAA-Ready Adobe Commerce.

Pharmacy 52

Pharmacy Science Regulations Marketing 52

Vial

MAY 13, 2024

Introduction The biopharma industry is poised to make revolutionary advances in and redefine drug development, and the current climate for innovation appears ideal. only 5% of molecules in oncology Phase I trials reach the market taking, on average, 7.5 According to Rodríguez-Molinero et al.,

Clinical Trials 52

Clinical Trials Trials Drug Development Production 52

Perficient: Drug Development

JANUARY 16, 2024

I worked in marketing and eCommerce when I interned at this medical supply company. Many durable medical equipment providers and pharmacies will leverage their distributor portal to order products on behalf of a customer. So, What Does This Have to Do with Adobe Commerce? There’s a reason this story is important and why I tell it.

Science 52

Science Nurses Production Pharmacy 52

Perficient: Drug Development

MARCH 19, 2024

See Also: Perficient Mentioned in Two Forrester Reports on Tech-Enabled Clinician Experiences Healthcare Trend #4: Experiences That Build Trust Historically, healthcare has experienced higher-than-average levels of consumer trust compared to other market sectors.

Pharmacy 52

Pharmacy Nurses Marketing Engineering 52

The Pharma Data

OCTOBER 30, 2020

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

Eventually, this is also going to revolutionize how fast an oncology drug can hit the market and introduce further competition to the pharmaceutical industry.”.

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceutical Companies 52

Codon

JULY 14, 2025

I could not find, that it hath, or ever had, any place in pharmacy, or any fuch qualities, as I fufpected afcribed to it by the botanifts. Drugs developed in Eichengrün’s laboratory were tested at Bayer’s pharmacological laboratory, led by Heinrich Dreser.

Treatment 63

Treatment Laboratories Disease Drugs 63

The Pharma Data

DECEMBER 17, 2020

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

DECEMBER 5, 2020

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

Production 40

Production Trials Treatment Disease 40

The Pharma Data

OCTOBER 28, 2020

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Virus 40

Virus Trials Clinical Trials Production 40

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. Read AgencyIQ analysis of a recent listening session on the topic here. ].

FDA 40

FDA Trials Therapies Regulations 40

Alta Sciences

MAY 15, 2023

TOP 5 WAYS INTEGRATED DRUG DEVELOPMENT SOLUTIONS SAVE YOU TIME AND MONEY aasimakopoulos Mon, 05/15/2023 - 16:06 Since 2004, the average cost of bringing a new drug to market has increased from $800 million to about $2.6 billion , without, for the most part, shorter development timelines. Altasciences has U.S.

Drug Development 52

Drug Development Clinical Trials Laboratories Compounding Pharmacies 52

Drug Target Review

AUGUST 30, 2024

I started by studying pharmaceutical sciences with the initial plan of becoming a pharmacist and owning my own pharmacy. However, I pursued an additional year in industrial pharmacy, where I learned a lot about manufacturing and drug development, which I found really fascinating.

Pharmacy 59

Pharmacy Engineering Pharmaceuticals Science 59

The Pharma Data

JANUARY 12, 2021

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Government 52

Government Hospitals Virus Clinical Trials 52

Agency IQ

OCTOBER 27, 2023

FDA is proposing to establish the criteria by which it would evaluate drug products and categories of drug products for inclusion on the list of drug products and categories of drug products that present demonstrable difficulties for compounding under section 503A and/or under section 503B.

FDA 40

FDA Science Regulations Production 40

Codon

FEBRUARY 13, 2024

To the question of how to turn this from an academic project into a marketable product, he suggests that a complete phage-testing and synthesis system, or a subscription-like service – with access to the phage-matching algorithms and all the necessary genetic data – could eventually attract major investors. (Its

Therapies 137

Therapies Virus DNA Clinical Trials 137

Agency IQ

DECEMBER 11, 2023

In addition, it may also be unethical to operate a control arm in some cases, such as when there is no currently marketed treatment option for a life-threatening disease. Pediatric patients: Likewise, reviewers from OCE have persistently voiced the need for pediatric patients to be included earlier in the drug development process as well.

FDA 40

FDA Science Clinical Trials Trials 40

Agency IQ

FEBRUARY 12, 2024

A new real-world evidence guidance on the list is meant to address the integration of randomized controlled trials for drug and biological products into routine clinical practice. Other guidances of note include one on the “study of sex differences in the clinical evaluation of medical products.”

Biosimilars 40

Biosimilars Science Clinical Pharmacology FDA 40

Agency IQ

FEBRUARY 15, 2024

If you’re looking for something specific, we recommend using the search function in your browser (Ctrl-F) to look for keywords of interest. Priority A List.

FDA 40

FDA Science Biosimilars Clinical Trials 40

The Pharma Data

NOVEMBER 20, 2020

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 5, 2020

Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Assets: Cash and marketable securities. $. Non-GAAP net income per share – diluted (1). $. Business Highlights. In millions). 5,901.0. $.

Production 40

Production FDA Trials FDA Approval 40

The Pharma Data

NOVEMBER 21, 2020

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

DECEMBER 29, 2020

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Agency IQ

SEPTEMBER 29, 2023

Due to the presence of nitrosamines in certain drug products, FDA had required that drug manufacturers conduct an initial risk assessment of approved or marketed products, with an initial completion date of October 1, 2021, and then confirmatory testing due by October 1, 2023. the drug and device) of the combination product.

FDA 40

FDA Science Regulations Production 40

Agency IQ

DECEMBER 1, 2023

FDA is proposing to establish the criteria by which it would evaluate drug products and categories of drug products for inclusion on the list of drug products and categories of drug products that present demonstrable difficulties for compounding under section 503A and/or under section 503B.

FDA 40

FDA Science Regulations Production 40

Perficient: Drug Development

MARCH 5, 2025

Welcome to our new series on Universal Design for Pharmacies! In this segment, well explore the importance of Universal Design in Pharmacies for All Disabilities.In Compliance with web accessibility guidelines (such as WCAG) helps pharmacies avoid legal issues and ensures that their online platforms are inclusive.

Pharmacy 52

Pharmacy Compliance Nurses Doctors 52

Perficient: Drug Development

MARCH 5, 2025

Welcome to our new series on Universal Design for Pharmacies! In this segment, well explore the importance of Universal Design in Pharmacies for All Disabilities. Universal design in pharmacies is essential for creating an inclusive and welcoming environment that caters to the needs of all customers, regardless of their abilities.

Pharmacy 52

Pharmacy Nurses Compliance Doctors 52

Perficient: Drug Development

FEBRUARY 4, 2025

Universal design is a crucial element in creating an inclusive and welcoming environment in pharmacies. By implementing universal design principles, pharmacies can significantly enhance the customer experience for individuals with disabilities and the broader community.

Pharmacy 52

Pharmacy Production Marketing 52

The Premier Consulting Blog

NOVEMBER 12, 2024

For drug developers the 505(b)(2) pathway presents an expedited pathway to FDA approval. De-mystifying the payer evaluation process of 505(b)(2)s A drug developer’s 505(b)(2) product is approved by FDA. If you are seeking support with defining, planning, and navigating the development process, contact us here.

Marketing 52

Marketing FDA Approval FDA Drugs 52

The Pharma Data

OCTOBER 14, 2020

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

FDA Approval 52

FDA Approval FDA Production Treatment 52

Drug Target Review

APRIL 11, 2025

Drug development is hampered by high costs, long timelines and a low probability of success and complex therapies exacerbate these challenges. Even excluding repositioned drugs, which could benefit from pre-existing toxicology and clinical data, a significant increase in PoS is still observed. This is an AI-generated image.

Clinical Development 97

Clinical Development Drugs Pharmaceuticals Clinical Trials 97

Drug Channels

FEBRUARY 3, 2025

Access USA unites PAP Patient Assistance & Access Programs , Hub and Specialty Pharmacy Models East and Rare Disease Summit : three influential access conferences under one roof for collaborative discussions and opportunities to establish powerful partnerships.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Government Regulations 52